



1652

Docket No. 23623-7043

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[X] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d) and § 1.8, I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: Aug. 21, 2002

Name of Person Certifying: Nancy Hine
Printed Name: Nancy Hine

In The United States Patent and Trademark Office

20

Applicants: J. Bryan Jones et al.

Assignee: The Governing Council of
the University of Toronto

File Date: November 9, 1999

Examiner: C. Patterson

Serial No.: 09/436,513

Group Art Unit: 1652

Title: Chemically Modified Mutant Serine Hydrolases Show Improved Catalytic
Activity and Chiral Selectivity

REQUEST FOR PERMISSION TO WITHDRAW AS ATTORNEY
(37 C.F.R. § 10.40(b))

1. I, an attorney signing below, respectfully request permission to withdraw from all further responsibility in this case, in accordance with 37 C.F.R. § 1.36.

LAST KNOWN ADDRESS OF CLIENT

2. The last known mailing address of the client is:

H. Thomas Anderton, Esq.
Patent Counsel
Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013

Correspondence should be directed to the following address:

H. Thomas Anderton, Esq.
Patent Counsel
Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013

BASIS FOR WITHDRAWAL REQUEST

3. The basis for the request for withdrawal is 37 C.F.R. § 10.40(b)(4).

Practitioner has been discharged by the client. Please see attached
disengagement letter, attached hereto.

RECEIVED
AUG 28 2002

APPROVED

William H. Hines
5825, TE/600
9/17/02

ALLOWANCE OF TIME FOR CLIENT TO ACT

4. Status of this Application: Pending. A response to the June 3, 2002 Office Action is due on December 3, 2002. Client Genencor International, Inc. ("Genencor") has full knowledge of all due dates regarding this response and has more than 90 days to respond. In addition, Genencor has a copy of the patent file, including the outstanding Office Action and has agreed and stated that it will take full responsibility for filing this response.

NOTIFICATION OF CLIENT

5. In accordance with 37 C.F.R. § 10.40(a), a copy of this request, including attachments, is being sent to the client.

A copy of the letter to the client is attached.

NUMBER OF COPIES OF REQUEST

6. This request is enclosed in triplicate.

RELATED APPLICATIONS

7. Related Applications for Which Withdrawal is Requested

Withdrawal also is requested in the following related application

<u>Application Number</u>	<u>Group</u>	<u>Status of Withdrawal Request</u>
---------------------------	--------------	-------------------------------------


N/A

CHANGE OF FIRM NAME

Attorney for applicant wishes to inform the Office that the firm name of McCutchen, Doyle, Brown & Enersen, LLP has been changed to Bingham McCutchen LLP.

SIGNATURE OF WITHDRAWING PRACTITIONER

8. I hereby apply to withdraw as attorney or agent for the above-identified patent application on behalf of myself and all attorneys of record associated with Customer No. 23639.

 Date: 8/21/02
 Michael J. Shuster, Ph.D. Reg. No. 41,310

Bingham McCutchen LLP
 Three Embarcadero Center, Suite 1800
 San Francisco, California 94111
 Telephone: (415) 393-2000
 Telefax: (415) 393-2286



Genencor International, Inc.

Legal

925 Page Mill Road
Palo Alto, California 94304
650.846.7500
650.845.6504 fax
www.genencor.com

July 23, 2002

VIA FACSIMILE
CONFIRMATION BY POST

Michael J. Shuster
Bingham McCutchen LLP
Three Embarcadero Center
San Francisco, CA 94111-4067

Re: University of Toronto and Dr. Bryan Jone's United States Patent Docket

Dear Michael:

As I mentioned to you in our conversation, Genencor has decided to bring these applications in-house purely for logistic reasons.

Bryan, Monique, Rick, and myself believe your work product has always been exceptional.


If there are any concerns or questions regarding the transfer of the applications to Genencor, please do not hesitate to give me a call.

Regards,



H. Thomas Anderton, Jr.
Patent Counsel

HTAjr/klg



BINGHAM McCUTCHEN

August 20, 2002

Direct: (415) 393-2651
michael.shuster@bingham.com

Bingham McCutchen LLP
Three Embarcadero Center
San Francisco, CA
94111-4067

415.393.2000
415.393.2286 fax

bingham.com

Boston
Hartford
London
Los Angeles
New York
San Francisco
Silicon Valley
Singapore
Walnut Creek
Washington

H. Thomas Anderton, Esq.
Patent Counsel
Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013

**Genencor International, Inc. – Transfer of US Files
23623-7000 Series**

Dear Tom:

Pursuant to an agreement between Bingham McCutchen LLP and Genencor International, Inc. we are transferring the US patent application files identified on the attached list to Genencor with the understanding that Genencor will assume responsibility for these US cases. We will be removing these matters from our docket and closing them in our systems as of August 30, 2002 (Friday).

We will send all of the original US patent application files and a copy of the current docket for these US applications listed on the attachment to you no later than August 28, 2002. Please verify that you received these files and docket by signing this letter in the space provided below and returning it to me.

Sincerely yours,


Michael J. Shuster

Enclosure

ACKNOWLEDGED, AGREED AND RECEIVED

H. Thomas Anderton, Esq.

RECEIVED
AUG 28 2002
TECH CENTER 1600/2900